Following Biogen’s recent failure of Aduhelm and a CEO resignation on the horizon, the drugmaker’s new Alzheimer’s drug candidate showed promising results in a phase 3 trial with a 27 percent slower cognitive decline.
Read the full post on Becker's Hospital Review - Healthcare News